Compare Enveric Biosciences Inc (ENVB) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs ON Holding AG — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while ON Holding AG trades at $34.18 (market cap $11.10B). The key difference: ON Holding AG is far larger — about 1659.2× Enveric Biosciences Inc's market cap, and ON Holding AG is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and ON Holding AG for 22 Days on average.
| ENVB | ONON | |
|---|---|---|
Market Cap | $6.69M | $11.10B |
Volume | 41,141 | 8,202,649 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $50.63 |
52-Week Low | $1.27 | $26.76 |
Typical Hold Time | 14 Days | 22 Days |
Enterprise Value | -$1.60M | $10.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
ONON trades at $33.22, up 0.27% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $0.44 vs. $0.42, maintaining a three-quarter beat streak. Recent investor day announcements include a $1 billion buyback program and ambitious 2029 targets of CHF 5.6B in sales with 22% EBITDA margins, driving positive sentiment.
The stock offers growth potential with 74% analyst buy ratings and a $42.26 consensus target, representing 27% upside. Key risks include elevated valuation multiples (P/E 23.41, P/S 5.52) and competitive pressure in footwear. Strong cash flow generation ($359.5M operating cash flow in 2025) supports the buyback and expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
